Ftse Mib
33.294,96
0,20%
DAX
19.146,17
0,76%
S&P 500
5.948,71
0,53%
NASDAQ
18.972,42
0,03%
Bitcoin
98.726,62
0,22%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Apollomics Inc (APLMW) Apollomics Inc (APLMW) Notizie

Apollomics Inc

APLMW
0,0061
-0,0039 (-39,00%)
21 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/11/202423:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202421:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/8/202416:50APSBiotech Sees Massive Buying Pressure Following Phase 2..
04/6/202414:00GLOBEApollomics Announces Vebreltinib Data at the 2024 American..
30/5/202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
29/5/202423:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/5/202414:00GLOBEApollomics Announces Presentation at the 2024 BIO..
24/5/202423:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202422:58EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/5/202422:32EDGAR2Form F-3 - Registration statement by foreign private issuers
20/5/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202422:05GLOBEApollomics Announces Private Placement Financing and..
25/4/202414:30GLOBEApollomics Announces Approval of Vebreltinib in China as a..
10/4/202413:00GLOBEApollomics Presents Vebreltinib Data at the 2024 American..
02/4/202414:00GLOBEApollomics Announces Poster Presentations of Vebreltinib..
28/3/202412:00GLOBEApollomics Highlights Clinical Progress and Reports Full..
26/3/202413:00GLOBEApollomics to Announce Full Year 2023 Financial Results and..
04/3/202413:00GLOBEApollomics Appoints Matthew Plunkett, Ph.D. as Chief..
07/2/202413:00GLOBEApollomics to Present at the Oppenheimer 34th Annual..
19/1/202422:15GLOBEApollomics Receives Nasdaq Notification Regarding Minimum..
17/1/202422:30GLOBEApollomics to Participate in a Fireside Chat at the B. Riley..
03/1/202413:00GLOBEApollomics Completes Enrollment in Phase 3 Bridging Study of..
02/1/202422:30GLOBEApollomics to Present at the 2024 Biotech Showcase
04/12/202313:00GLOBEApollomics Presents Interim Data from Two Ongoing Phase 2..
29/11/202313:30GLOBEApollomics to Participate in a Fireside Chat at the H.C...
28/11/202313:00GLOBEApollomics Announces Presentation of Vebreltinib Data at the..
Apertura: 0,0082 Min: 0,0082 Max: 0,01
Chiusura: 0,01

La tua Cronologia

NASDAQ
APLMW
Apollomics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network